Citius Oncology (CTOR) Competitors $2.00 +0.18 (+9.89%) Closing price 09/26/2025 04:00 PM EasternExtended Trading$1.97 -0.03 (-1.50%) As of 09/26/2025 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTOR vs. SVRA, ANAB, OLMA, OPT, BCAX, ARCT, ARVN, AQST, IVA, and ERASShould you be buying Citius Oncology stock or one of its competitors? The main competitors of Citius Oncology include Savara (SVRA), AnaptysBio (ANAB), Olema Pharmaceuticals (OLMA), Opthea (OPT), Bicara Therapeutics (BCAX), Arcturus Therapeutics (ARCT), Arvinas (ARVN), Aquestive Therapeutics (AQST), Inventiva (IVA), and Erasca (ERAS). These companies are all part of the "pharmaceutical products" industry. Citius Oncology vs. Its Competitors Savara AnaptysBio Olema Pharmaceuticals Opthea Bicara Therapeutics Arcturus Therapeutics Arvinas Aquestive Therapeutics Inventiva Erasca Savara (NASDAQ:SVRA) and Citius Oncology (NASDAQ:CTOR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings. Which has more volatility & risk, SVRA or CTOR? Savara has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Comparatively, Citius Oncology has a beta of 2.99, suggesting that its stock price is 199% more volatile than the S&P 500. Is SVRA or CTOR more profitable? Citius Oncology's return on equity of -51.93% beat Savara's return on equity.Company Net Margins Return on Equity Return on Assets SavaraN/A -69.05% -54.84% Citius Oncology N/A -51.93%-22.17% Which has preferable valuation & earnings, SVRA or CTOR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSavaraN/AN/A-$95.88M-$0.50-7.04Citius OncologyN/AN/AN/AN/AN/A Does the media refer more to SVRA or CTOR? In the previous week, Savara had 20 more articles in the media than Citius Oncology. MarketBeat recorded 28 mentions for Savara and 8 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 0.56 beat Savara's score of 0.21 indicating that Citius Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 1 Very Positive mention(s) 0 Positive mention(s) 24 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Citius Oncology 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals hold more shares of SVRA or CTOR? 87.9% of Savara shares are held by institutional investors. Comparatively, 70.5% of Citius Oncology shares are held by institutional investors. 5.3% of Savara shares are held by company insiders. Comparatively, 4.6% of Citius Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts rate SVRA or CTOR? Savara currently has a consensus price target of $7.50, suggesting a potential upside of 113.07%. Citius Oncology has a consensus price target of $6.00, suggesting a potential upside of 200.00%. Given Citius Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Citius Oncology is more favorable than Savara.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Savara 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Citius Oncology 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCitius Oncology beats Savara on 6 of the 10 factors compared between the two stocks. Get Citius Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CTOR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTOR vs. The Competition Export to ExcelMetricCitius OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$142.63M$3.07B$5.63B$10.31BDividend YieldN/A2.43%5.77%4.65%P/E RatioN/A21.1975.7526.14Price / SalesN/A260.75482.69102.00Price / CashN/A44.6837.1160.83Price / Book3.139.7412.416.36Net IncomeN/A-$52.93M$3.29B$270.97M7 Day Performance13.64%3.89%1.27%0.34%1 Month Performance-4.31%7.45%3.42%6.06%1 Year Performance42.86%18.28%63.28%27.34% Citius Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTORCitius Oncology2.4277 of 5 stars$2.00+9.9%$6.00+200.0%+39.9%$142.63MN/A0.00N/ANews CoverageAnalyst UpgradeGap UpSVRASavara2.5522 of 5 stars$3.50+0.1%$7.50+114.6%-17.0%$602.35MN/A-6.9720ANABAnaptysBio1.9771 of 5 stars$21.30-0.5%$46.13+116.6%-27.5%$597.07M$91.28M-4.76100OLMAOlema Pharmaceuticals2.9193 of 5 stars$8.86+6.3%$24.00+170.9%-22.2%$596.33MN/A-4.3970Positive NewsOPTOpthea0.4226 of 5 stars$3.41+7.2%$1.33-60.9%-14.8%$583.11M$30K0.008Gap UpHigh Trading VolumeBCAXBicara Therapeutics2.116 of 5 stars$10.62-1.2%$32.25+203.6%-54.4%$578.06MN/A-3.3432Positive NewsARCTArcturus Therapeutics2.7127 of 5 stars$20.91-0.6%$50.57+141.9%+1.8%$568.60M$152.31M-9.39180ARVNArvinas3.1627 of 5 stars$7.57+0.6%$17.13+126.2%-66.1%$556.16M$263.40M-7.50420Analyst DowngradeInsider TradeBuyback AnnouncementAQSTAquestive Therapeutics1.9543 of 5 stars$5.43+4.9%$10.29+89.6%+19.8%$544.97M$57.56M-7.81160Gap UpIVAInventiva3.0729 of 5 stars$5.67-5.8%$14.83+161.6%+245.7%$542.39M$9.95M0.00100News CoverageGap DownERASErasca2.4269 of 5 stars$1.85+3.7%$3.71+101.3%-23.2%$524.51MN/A-4.11120 Related Companies and Tools Related Companies Savara Competitors AnaptysBio Competitors Olema Pharmaceuticals Competitors Opthea Competitors Bicara Therapeutics Competitors Arcturus Therapeutics Competitors Arvinas Competitors Aquestive Therapeutics Competitors Inventiva Competitors Erasca Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTOR) was last updated on 9/27/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CTOR Stock Alerts